Overview
- The proposals would make hospitals that provide puberty blockers, hormone therapy or surgeries to patients under 18 ineligible to participate in Medicare and Medicaid and would bar Medicaid payment for those treatments.
- The FDA issued warning letters to 12 manufacturers and retailers over what it called illegal marketing of breast binders to children for gender dysphoria.
- The rules were entered into the Federal Register on Friday, triggering a formal 60-day public comment window while remaining unenforced.
- Major medical groups, including the American Academy of Pediatrics, denounced the plan as contrary to clinical consensus, while HHS points to its internal review concluding risks outweigh benefits for adolescents.
- The House passed separate bills to block Medicaid coverage of youth transition care and to make providing such care to minors a federal felony, sending both measures to the Senate.